Market revenue in 2023 | USD 2,776.8 million |
Market revenue in 2030 | USD 5,366.0 million |
Growth rate | 9.9% (CAGR from 2023 to 2030) |
Largest segment | Botulinum toxin type a |
Fastest growing segment | HA |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Collagen, Botulinum Toxin Type A, HA, CaHA, Polymer Fillers |
Key market players worldwide | Ipsen SA, AbbVie Inc, Medytox, Revance Therapeutics Inc, Galderma Group AG Registered Shares, Sinclair Pharma plc, Merz Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to facial injectable market will help companies and investors design strategic landscapes.
Botulinum toxin type a was the largest segment with a revenue share of 55.37% in 2023. Horizon Databook has segmented the Europe facial injectable market based on collagen, botulinum toxin type a, ha, caha, polymer fillers covering the revenue growth of each sub-segment from 2018 to 2030.
Dermal fillers or soft tissue fillers, especially nonsurgical procedure-based fillers, such as HA, collagen, Calcium Hydroxylapatite (CaHA), and polymer fillers, are gaining popularity in European countries. HAbased, dermal products are dominating the market in Europe owing to growing consumer demand coupled with a simple approval process established by the European Medicines Agency.
Currently, there are over 140 HA-based facial injectables approved in Europe. HA-based facial injectables such as JUVÉDERM VOLUMA (Allergan plc) and Restylane SubQ (Galderma S.A.), Juvéderm (Allergan plc), Mac Dermol (La Centrale des Peeling), Matridur (Florelle), Puragen (Mentor, U.S.), Rofilan (Rofil Medical International), TEOSYAL (Teoxane Laboratories), and Visagel (Dermatech) are significantly contributing to the market growth.
The region is expected to grow at a lucrative rate during the forecast period due to the presence of skilled professionals and rise in the geriatric population. Rising demand for advanced treatment technologies in Europe is a major factor anticipated to propel the market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe facial injectable market , including forecasts for subscribers. This continent databook contains high-level insights into Europe facial injectable market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account